| Document |
Document Title |
|
JP5616968B2 |
The present invention relates to a process for preparing 1-O-acyl-2-deoxy-2-ftuoro-4-thio-²-D-arabinofuranoses having formula I and intermediates thereof: wherein R 1 represents -C(O)-C 1 -C 6 -alkyl or -C(O)-aryl; and R 2 represents C ...
|
|
JP2014517000A |
The present invention describes the formula I: [Chemical 1]Provided are a substituted pyridine compound represented by the above or an N-oxide thereof or an agriculturally suitable salt (in the formula, the variable group in the formula ...
|
|
JP5522341B2 |
The present invention relates to spiro compounds of formula I, processes for their preparation, pharmaceutical compositions containing them as active ingredient, methods for the treatment of disease states such as cancers associated with...
|
|
JP5452165B2 |
Provided is a production method for a cis-QMF, which has a low environmental burden and is industrially advantageous. Specifically provided is a production method for a cis-type 2-alkylspiro(1,3-oxathiolane-5,3′)quinuclidine hydrochlor...
|
|
JP5432141B2 |
An acrylate derivative represented by the following general formula (1): (in the formula, R1 represents a hydrogen atom, a methyl group or a trifluoromethyl group; each of R2, R3, R5, R7, R8, R9 and R10 independently represents a hydroge...
|
|
JP2013542941A |
This invention provides compounds of formula I-A or I-B: wherein HY, G1, G2, R2, R12, W1, W2, n, and Ring A are as described in the specification. The compounds are inhibitors of PI3K and/or mTor and are thus useful for treating prolifer...
|
|
JP5355582B2 |
The present invention provides a novel benzodiazepine compound that blocks the IKur current or the Kv1.5 channel potently and more selectively than other K+ channels. The benzodiazepine compound of the invention is represented by General...
|
|
JP2013227269A |
To provide novel acrylic ester derivatives having excellent lithography properties such as LWR (Line Width Roughness) to achieve high resolution when used as one of the constituent units of a polymer compound to be contained in a photore...
|
|
JP5235859B2 |
The present invention provides a novel class of compounds that have the activity of inhibiting HSP90 enzyme and are useful as anti-cancer agents or such, and compounds that are useful as synthetic intermediates thereof. Specifically, the...
|
|
JP2013079232A |
To provide a photoacid generator that contains tailor-made photoacid generators having greater diffusion control and attendant properties such as resist profile.A photoacid generator compound has the formula (I): [A-(CHR1)p]k-(L)-(CH2)m-...
|
|
JP2013036006A |
To provide a compound that becomes a dye used in the field of a fiber material, a liquid crystal display device, and inkjet or the like, and in which the solubility to an organic solvent is high.The compound is shown by Formula (I). In t...
|
|
JP5053494B2 |
The present invention discloses a non-naturally occurring compound selected from the group consisting of compounds represented by the general formula (I) and stereoisomers and pharmaceutically acceptable salts thereof: where X is S, R 1 ...
|
|
JP5008812B2 |
Antitumor compounds have the five membered fused ring ecteinascidin structure of the formula (XIV). The present compounds lack a 1,4-bridging group as found in the ecteinascidins. They have at the C-1 position a substituent selected from...
|
|
JP4974415B2 |
The present invention relates to novel aryl-substituted S(O)m cycles of the formula (I):in whichF<1>, F<2>, G, V, W, X, Y, Z and m are each as defined in the description, to processes for their preparation and to their use in agriculture...
|
|
JP4955835B2 |
The invention relates to antibacterial compounds of formula I wherein R1 represents alkoxy (notably methoxy); R2 represents H or F; each of R3, R4, R5 and R6 represents independently H or D; V represents CH and W represents CH or N, or V...
|
|
JP4942900B2 |
A process step in the manufacture of an ecteinascidin compound comprising deprotecting a compound of formula (A) by removing both protecting groups in a single step to give an alpha aminolactone of formula (35), wherein ProtNH is an amin...
|
|
JP4917432B2 |
The present invention provides agents having antimicrobial activity for preventing and treating infectious diseases. Thus, the present invention provides novel substituted piperidino phenyloxazolidinone derivatives, processes for making ...
|
|
JP4911860B2 |
The present invention concerns compounds of formula (I) a stereochemically isomeric form thereof, an N-oxide form thereof or a pharmaceutically acceptable acid addition salt thereof, wherein -a1-a2-a3-a4- is a bivalent radical wherein on...
|
|
JP4889920B2 |
Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: ...
|
|
JP4841429B2 |
The present invention provides a compound of Formula I or Formula II: enantiomer, diastereomer, prodrug, solvate, metabolite, or pharmaceutically acceptable salt thereof, wherein constituent variables are provided herein. The compounds o...
|
|
JP2011236219A |
To provide a strong matrix metalloprotease inhibitor for treating a pathosis related to decomposition losing quick control of an extracellular matrix tissue.This invention relates to an aza spiro alkane compound and its enantiomer illust...
|
|
JP4808629B2 |
A method for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof; from a compound of the formula: (IV); wherein L represents a leaving group.
|
|
JP4690039B2 |
A process for the preparation of compounds of formula XIV starting from compounds of formula XIII wherein R 2 is an acyl group or an alcohol-protecting group; R 3 is hydrogen, acyl, alkyl or, taken together with R 4 , forms a C=O, C=S, S...
|
|
JP4680184B2 |
Sulfoderivatives of perylenetetracarboxylic acid dibenzimidazole are provided. These compounds form liquid crystal systems possessing high quality optical properties. The resulting liquid crystal systems are readily applicable onto a sub...
|
|
JP4654039B2 |
Spirotetrathiocarbamates (STOCs) or oxa substituted compounds (SOTOCs) of Formula I: Formula (I) or bisSTOC or bisSOTOC compounds of Formula II: Formula (II) wherein X1, X2, X3, X4, X5, X6, X7, and X8, are independently O or S; and prefe...
|
|
JP4597667B2 |
The present invention relates to new Macro-cycles of Formula (I), and their use for the treatment of cancer.
|
|
JP4583598B2 |
The purification and structure elucidation of several products of the metabolism of Et 743 by human cytochrome CYP3A4 have been accomplished. These compounds are abbreviated herein as "ETM" followed by a numeric value which represents th...
|
|
JP2010229136A |
To provide a modulator of a chemokine receptor mechanism.The compound is expressed by formula (1), provided that, Z is expressed by formula (2).
|
|
JP2010215656A |
To provide related structures having the same or higher level antitumor activities than conspicuous antitumor activities of the ecteinascidin (Et) 743 compound.Compounds having structural formula of the figure have the same or higher lev...
|
|
JP2010206080A |
To provide an organic transistor having high mobility and a large current on/off-ratio, and excellent in storage stability.The organic transistor has an organic semiconductor layer which contains at least one kind of a compound represent...
|
|
JP4503206B2 |
A method and composition for the treatment of humans infected with HIV that includes administration of an HIV treatment amount of an enantiomerically pure beta -D-dioxolanyl purine nucleoside of formula (I), wherein R is OH, Cl, NH2, or ...
|
|
JP4490421B2 |
The present invention provides a method for the treatment of schizophrenia which comprises administering a compound of formula wherein the substituents are as described herein or a pharmaceutically active acid-addition salt thereof. In p...
|
|
JP4476483B2 |
The present invention relates to 12,13-position modified epothilone derivatives, methods of preparation of the derivatives and intermediates therefor.
|
|
JP4447685B2 |
Novel dry skin remedies useful for treatment dry skin, containing as the active ingredient spiro Äoxathiolane-quinuclidineÜ derivatives represented by general formula (I) or acid addition salts thereof, desirably cis-2-methylspiro Ä1,...
|
|
JP4443043B2 |
The present application is directed to several newly prepared semi-synthetic ecteinascidin (Et) species, designated herein as Boc-Et 729, Et 875, and Et 1560. The physical properties of these compounds, their preparation and bioactivitie...
|
|
JP4397187B2 |
|
|
JP2009538298A |
The present invention provides novel tricyclic spiro-oxathiine naphthoquinone derivatives, a synthetic method for making the derivatives, and the use of the derivatives to induce cell death and/or to inhibit proliferation of cancer or pr...
|
|
JP2009536956A |
A method of treating the human body for cancer comprises administering an effective therapeutic amount of docetaxel in combination with an effective therapeutic amount of ET-743.
|
|
JP2009527591A |
Compounds useful in labeling biological materials are provided along with methods for their use.
|
|
JP4279561B2 |
Dihydropyrroloindoles and tetrahydropyridoindoles are prostaglandin receptor antagonists useful for the treatment of prostaglandin-mediated diseases such as allergic rhinitis, nasal congestion and asthma.
|
|
JP4280276B2 |
The present invention provides enantiomerically pure ²-D-(-)-dioxolane-nucleosides. The enantiomerically pure dioxolane nucleosides are active HIV agents, that are significantly more effective than the prior prepared racemic mixtures of...
|
|
JPWO2007049798A1 |
Equation (I)[In the formula, Ar indicates a benzene ring, etc., and X1Indicates nitrogen atom, sulfur atom, etc., and R1Indicates an aryl group, etc., and X2Is equation (II)(In the formula, R4And R5Indicates a lower alkyl group, etc., m ...
|
|
JPWO2007040166A1 |
Useful as a glucocorticoid receptor function regulator, anti-inflammatory drug, or anti-diabetic drug, formula (1):[In the formula, R1Is an aralkyl group, etc., R2Represents a hydrogen atom, etc., and "-W4= W5-W6= W7-"Is the expression: ...
|
|
JP2009067720A |
To provide a method for producing a new heterocyclic compound useful as a functional material and a synthetic intermediate therefor.Provided is a method for producing a compound (1) represented by the general formula, which comprises rea...
|
|
JP2009062317A |
To provide a thiophene derivative excellent in thermal stability and developing a photocyclization in a high quantum yield.This thiophene derivative is expressed by formulae [1] or [2].
|
|
JP4212576B2 |
To provide a 3-oxa-2-thiatricyclo[4.2.1.04,8]nonane derivative. The nonane derivative represented by formula [Rais H or an alkyl; R1, R2, R3, R4are each H, an alkyl; R5, R6, R7are H, an alkyl, a substituted oxycarbonyl, cyano; X is methy...
|
|
JP4183099B2 |
Epothilone derivatives of formula (I)-(III) are new. R = H or 1-4C alkyl; Y Z = H, halo, pseudohalogen, OH, 1-6C acyloxy, 1-6C alkoxy or benzoyloxy; or Y+Z = bond or O; (a) R' = Q; A = H; B = OR1; and R" = R2; or R"+B = C(O)O, C(S)O, S(O...
|
|
JP4115529B2 |
Farnesyl protein transferase inhibitors e.g. of formula (I) and (II) and their enantiomers, diastereomers, salts, prodrugs and solvates are new: G = a group of formula (i): m, n, r, s, t = 0 or 1; p = 0-2; V, W, X = O, H, R1, R2 or R3; Z...
|
|
JP4112001B2 |
PCT No. PCT/EP96/01919 Sec. 371 Date Aug. 5, 1997 Sec. 102(e) Date Aug. 5, 1997 PCT Filed May 5, 1996 PCT Pub. No. WO96/36622 PCT Pub. Date Nov. 21, 1996The present invention relates to novel 10-deacetyl-14 beta -hydroxybaccatine III der...
|
|
JP4054376B2 |
The present invention relates to certain novel triaryl methyl free radicals and their use as image enhancing agents in magnetic resonance imaging (MRI) as well as to contrast media containing such radicals and to the use of such radicals...
|
